MARKET

RDHL

RDHL

Redhill Biopharm
NASDAQ
0.5299
+0.0178
+3.48%
After Hours: 0.5299 0 0.00% 16:07 03/28 EDT
OPEN
0.5000
PREV CLOSE
0.5121
HIGH
0.5499
LOW
0.5000
VOLUME
462.51K
TURNOVER
0
52 WEEK HIGH
4.980
52 WEEK LOW
0.2570
MARKET CAP
15.74M
P/E (TTM)
-0.1269
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at RDHL last week (0318-0322)?
Weekly Report · 4d ago
RedHill Biopharma Share Capital Increase Approved
TipRanks · 03/21 20:57
RedHill Biopharma Reschedules Shareholders Meeting
TipRanks · 03/20 21:58
Weekly Report: what happened at RDHL last week (0311-0315)?
Weekly Report · 03/18 10:29
BRIEF-Redhill Biopharma Got Letter From Nasdaq Indicating Bid Price For ADSS Had Closed Below Minimum Requirement For Continued Listing On March 11
Redhill Biopharma Got Letter From Nasdaq Indicating Bid Price For ADSS Had Closed Below Minimum Requirement For Continued Listing On March 11. Company says it got letter from Nasdaq saying bid price for ADSS had closed below minimum requirement for continued listing.
Reuters · 03/14 21:27
Weekly Report: what happened at RDHL last week (0304-0308)?
Weekly Report · 03/11 10:27
RedHill Biopharma Will Be Issued U.S. Patent Number 11,918,560 Tomorrow Titled "Serine Protease Inhibitor For Treating Coronavirus Infection"
Benzinga · 03/04 17:35
Weekly Report: what happened at RDHL last week (0226-0301)?
Weekly Report · 03/04 10:29
More
About RDHL
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.

Webull offers RedHill Biopharma Ltd (ADR) stock information, including NASDAQ: RDHL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RDHL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RDHL stock methods without spending real money on the virtual paper trading platform.